Morning Call May 22
Health Care: Drugs
Vical Incorporated (VICL: NASDAQ)
$3.65 0.02 | 0.55%
05/22/13 - 11:30 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.63 |
| 52 Week High | 4.74 |
| 52 Week Low | 2.61 |
| Avg. Daily Vol. (Mil) | 0.67 |
| Beta (3 year) | 1.22 |
| Share Related Items | |
| Mkt Cap (Mil) | 313.81 |
| Shares Out (Mil) | 86.45 |
| Float (Mil) | 75.34 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 14.00 |
| Current Ratio | 14.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 41.11 |
| Price/Book | 3.87 |
| Price/Cash Flow | -13.90 |
| Per Share Data | |
| Earnings | -0.38 |
| Sales | 0.09 |
| Book Value | 0.94 |
| Cash Flow | -0.26 |
| Business Summary | |
|---|---|
| Vical Incorporated researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. | |
| General Information | |
| 10390 Pacific Center Court
San Diego, CA 92121-4340 |
|
| www.vical.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 118 | |
| CEO: Mr. Vijay B. Samant | |
| Short Interest | |
| Current Month (Mil) | 7.46 |
| Previous Month (Mil) | 6.15 |
| Short Interest Ratio (Days) | 11.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -27.90 |
| Return on Investments | -30.00 |
| Profitability | |
| Gross Margin | -22.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with VICL
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor22 Biopharma Stocks With Br...
- UserO4 Investing
- ContributorStocks With Big Insider Buy...
- Contributor10 Best-Performing Stocks U...
- ContributorRelative Strength Stocks 09...
- ContributorCancer Drug Stocks to Trade...
- ContributorBreakout Stocks Of The Week...
- ContributorDollar Store
Latest VICL Headlines from TheStreet
- 6 Stocks Under $10 Spiking Higher 04.04.13 | 03:04 pm
- 16 Stocks Under $5 Trading At Discounts To Target Price 03.26.13 | 12:03 pm
- Vical To Present At March Investor Conferences 02.27.13 | 06:02 am
- Vical Reports 2012 Financial Results And Progress In Key Development Programs 02.06.13 | 06:02 am
- Vical To Present At February Investor Conferences 02.05.13 | 06:02 am
- Vical Announces Publication Of Herpes Simplex Vaccine Guinea Pig Study Data 02.04.13 | 06:02 am
- Vical Announces News Release And Conference Call Schedule For 2012 Financial Results 01.30.13 | 06:01 am
- 3 Pharma Stocks Under $5 Trading Higher 01.15.13 | 02:01 pm
- Vical To Present At 31st Annual J.P. Morgan Healthcare Conference 01.03.13 | 06:01 am
- Vical Named To NASDAQ Global Select Market 01.02.13 | 06:01 am
Press Releases for VICL
- MERIAL Receives Full License Approval For ONCEPT(TM) Canine Melanoma Vaccine - PR Newswire 02.16.10 | 08:02 am
Partner Headlines for VICL
- Vical and Bristol-Myers Ink Deal - Analyst Blog - NASDAQ 09.17.12 | 07:09 pm
- Abbott-Astellas Collaborate - Analyst Blog - NASDAQ 09.13.12 | 10:09 pm
- Abbott-Astellas Collaborate - Analyst Blog - Zacks 09.13.12 | 06:09 pm
- 3 Vaccine Companies With Upcoming Catalysts - Seeking Alpha 09.09.12 | 08:09 am
- 3 Speculative Biotechs Worth Watching - Seeking Alpha 07.08.12 | 08:07 am
- Vical Back On The Move - Seeking Alpha 11.04.11 | 06:11 pm
- Vical: Making Progress In The Area Of HSV-2 Vaccines - Seeking Alpha 08.26.11 | 10:08 pm
- 5 Healthcare Stocks of Interest This Week - Seeking Alpha 07.15.11 | 06:07 pm
- Vical Is Deeply Undervalued: Technology and Pipeline Offer Upside Reward - Seeking Alpha 03.29.11 | 08:03 am
- Ipilimumab Approval Highlights Active Immunotherapy Renaissance - Seeking Alpha 03.27.11 | 08:03 am
